Crohn’s Disease
Peptimmune is conducting research with PI-2301 and its effect on Crohn’s disease
Disease overview
Crohn’s disease is a chronic inflammatory disorder of the gastrointestinal (GI) tract. Although it can involve any area of the GI tract from the mouth to the anus, it most commonly affects the small intestine and/or colon. Crohn’s and a related disease, ulcerative colitis, are the two main disease categories that belong to a larger group of illnesses called inflammatory bowel disease (IBD). In people with Crohn’s disease, however, the immune system reacts inappropriately. Researchers believe that the immune system mistakes microbes, such as bacteria that is normally found in the intestines, for foreign or invading substances, and launches an attack. In the process, the body sends white blood cells into the lining of the intestines, where they produce chronic inflammation.
Current treatment
- Immunomodulatory and immunosuppressive agents can induce remission and affect the course and progression of the disease.
- Many patients show good control of disease activity with these treatments; others continue to experience frequent relapses, active disease on Crohn’s Disease Activity Index (CDAI), and progression of disability.
- Some approved drugs that help ameliorate the symptoms of Crohn’s disease are often associated with numerous untoward side effects and require frequent injections or infusions.
For more information about Crohn’s disease, please visit www.CCFA.org.
Peptimmune is conducting research with PI-2301 and its effect on Crohn’s disease
